Restless legs syndrome and periodic leg movements in sleep

Handbook of Clinical Neurology

Volumn 99, Issue C, 2011, Pages 913-948

  Earley, Christopher J ^a   Allen, Richard P ^a   Hening, Wayne ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOOK; GENETICS; HISTORY; HUMAN; LEG; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PERIODICITY; PHYSIOLOGY; RESTLESS LEGS SYNDROME;

ACTIVITY CYCLES; HISTORY, 17TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEG; MOVEMENT; RESTLESS LEGS SYNDROME;

EID: 78149372689     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52007-4.00015-1     Document Type: Book

References (268)

1. Abele M., Burk K., Laccone F., et al. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol 2001, 248:311-314.
2. Abetz L., Allen R., Follet A., et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004, 26:925-935.
3. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide [letter]. Arch Neurol 1982, 39:739.
4. Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987, 10:69-79.
5. Allen R., Becker P.M., Bogan R., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004, 27:907-914.
6. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
7. Allen R.P., Earley C.J. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000, 1:11-19.
8. Allen R.P., Earley C.J. Validation of the Johns Hopkins restless legs severity scale. Sleep Med 2001, 2:239-242.
9. Allen R.P., Barker P.B., Wehrl F., et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265.
10. Allen R.P., La Buda M.C., Becker P., et al. Family history study of the restless legs syndrome. Sleep Med 2002, 3(Suppl):S3-S7.
11. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
12. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
13. Allen R.P., Connor J.R., Hyland K., et al. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009, 10:123-128.
14. International Classification of Sleep Disorders: Diagnostic and Coding Manual 2005, American Academy of Sleep Medicine, American Academy of Sleep Medicine, Westchester, IL.
15. Ancoli-Israel S., Kripke D.F., Klauber M.R., et al. Periodic limb movements in sleep in community dwelling elderly. Sleep 1991, 14:496-500.
16. Askenasy J.J. Approaching disturbed sleep in late Parkinson's disease: first step toward a proposal for a revised UPDRS. Parkinsonism Relat Disord 2001, 8:123-131.
17. Aspenstroem G. Pica and restless legs in iron deficiency. Sven Lakartidn 1964, 61:1174-1177.
18. Atkinson M.J., Allen R.P., DuChane J., et al. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res 2004, 13:679-693.
19. Ausserwinkler M., Schmidt P. [Successful clonidine treatment of restless leg syndrome in chronic kidney insufficiency.]. Schweiz Med Wochenschr 1989, 119:184-186.
20. Bara-Jimenez W., Aksu M., Graham B., et al. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000, 54:1609-1616.
21. Barker A.T., Jalinous R., Freeston I.L. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985, 1:1106-1107.
22. Bassetti C.L., Mauerhofer D., Gugger M., et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001, 45:67-74.
23. Bateman D.N., Kahn C., Mashiter K., et al. Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Br J Clin Pharmacol 1978, 6:401-407.
24. Bateman D.N., Kahn C., Davies D.S. Concentration effect studies with oral metoclopramide. Br J Clin Pharmacol 1979, 8:179-182.
25. Benes H., Kurella B., Kummer J., et al. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999, 22:1073-1081.
26. Benes H., Heinrich C.R., Ueberall M.A., et al. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004, 27:674-682.
27. Benz R.L., Pressman M.R., Hovick E.T., et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999, 34:1089-1095.
28. Berger K., von Eckardstein A., Trenkwalder C., et al. Iron metabolism and the risk of restless legs syndrome in an elderly general population - the MEMO-Study. J Neurol 2002, 249:1195-1199.
29. Berger K., Luedemann J., Trenkwalder C., et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004, 164:196-202.
30. Bhowmik D., Bhatia M., Gupta S., et al. Restless legs syndrome in hemodialysis patients in India: a case controlled study. Sleep Med 2003, 4:143-146.
31. Birinyi P.V., Allen R.P., Lesage S., et al. Investigation into the correlation between sensation and leg movement in restless legs syndrome. Mov Disord 2005, 20:1097-1103.
32. Bjorvatn B., Leissner L., Ulfberg J., et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 2005, 6:307-312.
33. Blom S., Ekbom K.A. Comparison between akathisia developing on treatment with phenothiazine derivatives and the restless legs syndrome. Acta Med Scand 1961, 170:689-694.
34. Bonati M.T., Ferini-Strambi L., Aridon P., et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003, 126:1485-1492.
35. Botez M.I., Lambert B. Folate deficiency and restless legs syndrome in pregnancy. N Engl J Med 1977, 297:670.
36. Brodeur C., Montplaisir J., Godbout R., et al. Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: a double-blind, controlled study. Neurology 1988, 38:1845-1848.
37. Bucher S., Seelos K., Oertel W., et al. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997, 41:639-645.
38. Buchfuhrer M.J., Gunzel J. Non-pharmacologic considerations and treatment of RLS. The Restless Legs Syndrome 2009, 228-237. Butterworth, Philadelphia. W.A. Hening, R.P. Allen, S. Chokroverty, C.J. Earley (Eds.).
39. Carrier J., Frenette S., Montplaisir J., et al. Effects of periodic leg movements during sleep in middle-aged subjects without sleep complaints. Mov Disord 2005, 20:1127-1132.
40. Carskadon M.A., Brown E.D., Dement W.C. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol Aging 1982, 3:321-327.
41. Chabli A., Michaud M., Montplaisir J. Periodic arm movements in patients with the restless legs syndrome. Eur Neurol 2000, 44:133-138.
42. Chen S., Ondo W.G., Rao S., et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004, 74:876-885.
43. Cheshire W.P. Hypotensive akathisia: autonomic failure associated with leg fidgeting while sitting. Neurology 2000, 55:1923-1926.
44. Chesson A.L., Wise M., Davila D., et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999, 22:961-968.
45. Cho Y.W., Shin W.C., Yun C.H., et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008, 31:219-223.
46. Coleman R.M., Pollak C.P., Weitzman E.D. Periodic movements in sleep (nocturnal myoclonus): relations to sleep disorders. Ann Neurol 1980, 8:416-421.
47. Collado-Seidel V., Kohnen R., Samtleben W., et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998, 31:324-328.
48. Collado-Seidel V., Kazenwadel J., Wetter T.C., et al. A controlled study of additional sr-l-dopa in l-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999, 52:285-290.
49. Connor J.R., Boyer P.J., Menzies S.L., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
50. Connor J.R., Wang X.S., Patton S.M., et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004, 62:1563-1567.
51. Danoff S.K., Grasso M.E., Terry P.B., et al. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001, 120:313-316.
52. de Mello M.T., Poyares D.L., Tufik S. Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions. Spinal Cord 1999, 37:634-637.
53. de Mello M.T., Silva A.C., Esteves A.M., et al. Reduction of periodic leg movement in individuals with paraplegia following aerobic physical exercise. Spinal Cord 2002, 40:646-649.
54. de Mello M.T., Esteves A.M., Tufik S. Comparison between dopaminergic agents and physical exercise as treatment for periodic limb movements in patients with spinal cord injury. Spinal Cord 2004, 42:218-221.
55. Desautels A., Turecki G., Montplaisir J., et al. Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology 2001, 57:1304-1306.
56. Desautels A., Turecki G., Montplaisir J., et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001, 69:1266-1270.
57. Desautels A., Turecki G., Montplaisir J., et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 2002, 59:215-219.
58. Desautels A., Turecki G., Montplaisir J., et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005, 62:591-596.
59. de Weerd A.W., Rijsman R.M., Brinkley A. Activity patterns of leg muscles in periodic limb movement disorder. J Neurol Neurosurg Psychiatry 2004, 75:317-319.
60. Dhanuka A.K., Singh G. Periodic limb movement disorder: a clinical and polysomnographic study. Neurol India 2001, 49:366-370.
61. Durmer J.S., Dinges D.F. Neurocognitive consequences of sleep deprivation. Semin Neurol 2005, 25:117-129.
62. Earley C.J. Clinical practice. Restless legs syndrome. N Engl J Med 2003, 348:2103-2109.
63. Earley C.J. Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep Med 2005, 6:475.
64. Earley C.J., Allen R.P. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996, 19:801-810.
65. Earley C.J., Yaffee J.B., Allen R.P. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998, 51:1599-1602.
66. Earley C.J., Allen R.P., Beard J.L., et al. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000, 62:623-628.
67. Earley C.J., Connor J.R., Beard J.L., et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000, 54:1698-1700.
68. Earley C.J., Hyland K., Allen R.P. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov Disord 2001, 16:144-149.
69. Earley C.J., Heckler D., Horská A., et al. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004, 5:231-235.
70. Earley C.J., Barker P.B., Horská A., et al. MRI-determined regional brain iron concentrations in early and late-onset restless legs syndrome. Sleep Med 2005, 7:458-461.
71. Earley C.J., Connor J.R., Beard J.L., et al. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 2005, 28:1069-1075.
72. Earley C.J., Heckler D., Allen R.P. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005, 6:301-305.
73. Earley C.J., Hyland K., Allen R.P. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006, 7:263-268.
74. Ehrenberg B.L., Eisensehr I., Corbett K.E., et al. Valproate for sleep consolidation in periodic limb movement disorder. J Clin Psychopharmacol 2000, 20:574-578.
75. Eisensehr I., Wetter T.C., Linke R., et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001, 57:1307-1309.
76. Eisensehr I., Ehrenberg B.L., Rogge Solti S., et al. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004, 251:579-583.
77. Ekbom K.A. Restless Legs 1945, Ivar Haeggströms, Stockholm.
78. Ekbom K.A. Restless legs syndrome. Neurology 1960, 10:868-873.
79. Ekbom K.A. Restless legs. Handbook of Clinical Neurology 1970, 311-320. North Holland Publishing Company, Amsterdam. P. Vinken, G. Bruyn (Eds.).
80. Entezari-Taher M., Singleton J.R., Jones C.R., et al. Changes in excitability of motor cortical circuitry in primary restless legs syndrome. Neurology 1999, 53:1201-1205.
81. Etgen T., Draganski B., Ilg C., et al. Bilateral thalamic gray matter changes in patients with restless legs syndrome. Neuroimage 2005, 24:1242-1247.
82. Evidente V.G. Piribedil for restless legs syndrome: a pilot study. Mov Disord 2001, 16:579-581.
83. Evidente V.G., Adler C.H., Caviness J.N., et al. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000, 15:324-327.
84. Exar E.N., Collop N.A. The association of upper airway resistance with periodic limb movements. Sleep 2001, 24:188-192.
85. Filho G.S.G., Gorini C.C., Purysko A.S., et al. Restless legs syndrome in patients on chronic hemodialysis in a Brazilian city. Arq Neuropsiquiatr 2005, 61:723-727.
86. Garcia-Borreguero D., Larrosa O., de la Llave Y., et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002, 59:1573-1579.
87. Garcia-Borreguero D., Larrosa O., Granizo J.J., et al. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep 2004, 27:669-673.
88. Gemignani F., Marbini A., Di Giovanni G., et al. Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology 1999, 52:1064-1066.
89. Gigli G.L., Adorati M., Dolso P., et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004, 5:309-315.
90. Goodman J.D., Brodie C., Ayida G.A. Restless leg syndrome in pregnancy. BMJ 1988, 297:1101-1102.
91. Greenspan S.L., Klibanski A., Rowe J.W., et al. Age alters pulsatile prolactin release: influence of dopaminergic inhibition. Am J Physiol 1990, 258:E799-E804.
92. Grewal M., Hawa R., Shapiro C. Treatment of periodic limb movements in sleep with selegiline HCl. Mov Disord 2002, 17:398-401.
93. Guilleminault C., Cetel M., Philip P. Dopaminergic treatment of restless legs and rebound phenomenom. Neurology 1993, 43:445.
94. Happe S., Klosch G., Saletu B., et al. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001, 57:1717-1719.
95. Haug B.A., Schonle P.W., Knobloch C., et al. Silent period measurement revives as a valuable diagnostic tool with transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1992, 85:158-160.
96. Hening W., Walters A.S., Allen R.P., et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004, 5:237-246.
97. Hening W.A., Walters A., Kavey N., et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology 1986, 36:1363-1366.
98. Hening W.A., Walters A.S., Wagner M., et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 1999, 22:901-912.
99. Hening W.A., Washburn T., Somel D., et al. Restless legs patients with a younger age of onset have an increased frequency of affected relatives. Neurology 2003, 60:A11.
100. Hening W.A., Mathias R.A., Allen R.P., et al. A segregation analysis of restless leg syndrome families. Neurology 2005, 64(Supp1):140. (abstract).
101. Hening W.A., Allen R.P., Washburn M., et al. The four diagnostic criteria for the Restless Legs Syndrome are unable to exclude confounding conditions (" mimics" ). Sleep Med 2009, 10:976-981.
102. Hilbert J., Mohsenin V. Can periodic limb movement disorder be diagnosed without polysomnography? A case-control study. Sleep Med 2003, 4:35-41.
103. Hogl B., Kiechl S., Willeit J., et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005, 64:1920-1924.
104. Horvath J., Fross R.D., Kleiner-Fisman G., et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004, 19:656-662.
105. Hui D.S., Wong T.Y., Ko F.W., et al. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000, 36:783-788.
106. Iannaccone S., Zucconi M., Marchettini P., et al. Evidence of peripheral axonal neuropathy in primary restless legs syndrome. Mov Disord 1995, 10:2-9.
107. Inoue Y., Mitani H., Nanba K., et al. Treatment of periodic leg movement disorder and restless leg syndrome with talipexole. Psychiatry Clin Neurosci 1999, 53:283-285.
108. Jones B.C., Reed C.L., Hitzemann R., et al. Quantitative genetic analysis of ventral midbrain and liver iron in BXD recombinant inbred mice. Nutr Neurosci 2003, 6:369-377.
109. Kageyama T., Kabuto M., Nitta H., et al. Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci 2000, 54:296-298.
110. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 2004, 43:671-684.
111. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., et al. Time-dependent associations between indices of iron store and mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3070-3080.
112. Kammer T., Beck S., Thielscher A., et al. Motor thresholds in humans: a transcranial magnetic stimulation study comparing different pulse waveforms, current directions and stimulator types. Clin Neurophysiol 2001, 112:250-258.
113. Kaplan P.W., Allen R.P., Buchholz D.W., et al. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993, 16:717-723.
114. Kavanagh D., Siddiqui S., Geddes C.C. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004, 43:763-771.
115. Kim J., Choi C., Shin K., et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry Clin Neurosci 2005, 59:350-353.
116. Konofal E., Lecendreux M., Arnulf I., et al. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2004, 158:1113-1115.
117. Kotagal S., Silber M.H. Childhood-onset restless legs syndrome. Ann Neurol 2004, 56:803-807.
118. Krishnan P.R., Bhatia M., Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003, 18:181-185.
119. Kryger M.H., Otake K., Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med 2002, 3:127-132.
120. Kujirai T., Caramia M.D., Rothwell J.C., et al. Corticocortical inhibition in human motor cortex. J Physiol 1993, 471:501-519.
121. Kukowski B., Haug B. Quantitative evaluation of the silent period, evoked by transcranial magnetic stimulation during sustained muscle contraction, in normal man and in patients with stroke. Electromyogr Clin Neurophysiol 1992, 32:373-378.
122. Kutner N., Bliwise D. Restless legs complaint in African-American and Caucasian hemodialysis patients. Sleep Med 2002, 3:497-500.
123. Lang A.E. Akathisia and the restless legs syndrome. Parkinson's Disease and Movement Disorders 1993, 399-418. William & Wilkins, Baltimore. 2nd edn. J. Jankovic, E. Tolosa (Eds.).
124. Lauerma H., Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999, 60:241-244.
125. Levchenko A., Montplaisir J.Y., Dube M.P., et al. The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 2004, 55:887-891.
126. Li J., Hu L.D., Wang W.J., et al. Linkage analysis of the candidate genes of familial restless legs syndrome. Yi Chuan Xue Bao 2003, 30:325-329.
127. Littner M.R., Kushida C., Anderson W.M., et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004, 27:557-559.
128. Lugaresi E., Coccagna G., Berti Ceroni G., et al. Restless legs syndrome and nocturnal myoclonus. The Abnormalites of Sleep in Man 1968, 285-294. Aulo Gaggi Editore, Bologna. H. Gastaut, E. Lugaresi, G. Berti Ceroni (Eds.).
129. Lugaresi E., Cirignotta F., Coccagna G., et al. Nocturnal myoclonus and restless legs syndrome. Adv Neurol 1986, 43:295-307.
130. Ma J., Wehrli F.E. Method for image-based measurement of the reversible and irreversible contribution to the transverse relaxation rate. J Magn Reson B 1996, 111:61-69.
131. Mahowald M.W. Con: assessment of periodic leg movements is not an essential component of an overnight sleep study. Am J Respir Crit Care Med 2001, 164:1340-1341.
132. Manconi M., Govoni V., De Vito A., et al. Restless legs syndrome and pregnancy. Neurology 2004, 63:1065-1069.
133. Manconi M., Govoni V., De Vito A., et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 2004, 5:305-308.
134. Martinez S., Guilleminault C. Periodic leg movements in prepubertal children with sleep disturbance. Dev Med Child Neurol 2004, 46:765-770.
135. Michaud M., Chabli A., Lavigne G., et al. Arm restlessness in patients with restless legs syndrome. Mov Disord 2000, 15:289-293.
136. Michaud M., Poirier G., Lavigne G., et al. Restless legs syndrome: scoring criteria for leg movements recorded during the suggested immobilization test. Sleep Med 2001, 2:317-321.
137. Michaud M., Lavigne G., Desautels A., et al. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov Disord 2002, 17:112-115.
138. Michaud M., Paquet J., Lavigne G., et al. Sleep laboratory diagnosis of restless legs syndrome. Eur Neurol 2002, 48:108-113.
139. Michaud M., Soucy J.P., Chabli A., et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002, 249:164-170.
140. Michaud M., Dumont M., Selmaoui B., et al. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 2004, 55:372-380.
141. Micozkadioglu H., Ozdemir F.N., Kut A., et al. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study. Ren Fail 2004, 26:393-397.
142. Miranda M., Araya F., Castillo J.L., et al. [Restless legs syndrome: a clinical study in adult general population and in uremic patients.]. Rev Med Chil 2001, 129:179-186.
143. Mizuno S., Mihara T., Miyaoka T., et al. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 2005, 14:43-47.
144. Molnar M.Z., Novak M., Ambrus C., et al. Restless legs syndrome in patients after renal transplantation. Am J Kidney Dis 2005, 45:388-396.
145. Montplaisir J., Godbout R., Poirier G., et al. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with l-dopa. Clin Neuropharmacol 1986, 9:456-463.
146. Montplaisir J., Boucher S., Poirier G., et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997, 12:61-65.
147. Montplaisir J., Boucher S., Nicolas A., et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord 1998, 13:324-329.
148. Montplaisir J., Nicolas A., Denesle R., et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999, 52:938-943.
149. Montplaisir J., Denesle R., Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000, 7(Suppl 1):27-31.
150. Montplaisir J., Michaud M., Denesle R., et al. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med 2000, 1:163-167.
151. Morse A.C., Beard J.L., Jones B. Sex and genetics are important cofactors in assessing the impact of iron deficiency on the developing rat brain. Nutr Neurosci 1999, 2:323-335.
152. Mosko S.S., Dickel M.J., Paul T., et al. Sleep apnea and sleep-related periodic leg movements in community resident seniors. J Am Geriatr Soc 1988, 36:502-508.
153. Mucke H.A. Rotigotine Schwarz Pharma. IDrugs 2003, 6:894-899.
154. Nichols D.A., Allen R.P., Grauke J.H., et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003, 163:2323-2329.
155. Nicolas A., Lesperance P., Montplaisir J. Is excessive daytime sleepiness with periodic leg movements during sleep a specific diagnostic category?. Eur Neurol 1998, 40:22-26.
156. Nomura T., Inoue Y., Kusumi M., et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord 2008, 23:2363-2369.
157. Nordlander N.B. Therapy in restless legs. Acta Med Scand 1953, 145:453-457.
158. Nordlander N.B. Restless legs. Br J Phys Med 1954, 17:160-162.
159. O'Keeffe S.T. Secondary causes of restless legs syndrome in older people. Age Ageing 2005, 34:349-352.
160. O'Keeffe S.T., Noel J., Lavan J.N. Restless legs syndrome in the elderly. Postgrad Med J 1993, 69:701-703.
161. O'Keeffe S.T., Gavin K., Lavan J.N. Iron status and restless legs syndrome in the elderly. Age Ageing 1994, 23:200-203.
162. Ondo W.G. Methadone for refractory restless legs syndrome. Mov Disord 2005, 20:345-348.
163. Ondo W.G., Vuong K.D., Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002, 59:421-424.
164. Ondo W., Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996, 47:1435-1441.
165. Ondo W., Tan E.K., Mansoor J. Rheumatologic serologies in secondary restless legs syndrome. Mov Disord 2000, 15:321-323.
166. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004, 1012:1-13.
167. Pearson V., Allen R.P., Dean T., et al. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med 2006, 7:25-30.
168. Pennestri M.H., Whittom S., Adam B., et al. PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep 2006, 29:1183-1187.
169. Phillips B., Young T., Finn L., et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000, 160:2137-2141.
170. Picchietti D., Allen R.P., Walters A.S., et al. Restless legs syndrome: prevalence and impact in children and adolescents - the Peds REST study. Pediatrics 2007, 120:253-266.
171. Picchietti D.L., Walters A.S. Moderate to severe periodic limb movement disorder in childhood and adolescence. Sleep 1999, 22:297-300.
172. Poewe W., Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004, 63:S12-S16.
173. Polydefkis M., Allen R.P., Hauer P., et al. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology 2000, 55:1115-1121.
174. Practice parameters for the indications for polysomnography and related procedures. Sleep 1997, 20:406-422. Polysomnography Task Force, American Sleep Disorders Association Standards of Practice Committee.
175. Provini F., Vetrugno R., Meletti S., et al. Motor pattern of periodic limb movements during sleep. Neurology 2001, 57:300-304.
176. Quatrale R., Manconi M., Gastaldo E., et al. Neurophysiological study of corticomotor pathways in restless legs syndrome. Clin Neurophysiol 2003, 114:1638-1645.
177. Ratey J.J., Salzman C. Recognizing and managing akathisia. Hosp Community Psychiatry 1984, 35:975-977.
178. Rau C., Hummel F., Gerloff C. Cortical involvement in the generation of " involuntary" movements in restless legs syndrome. Neurology 2004, 62:998-1000.
179. Read D.J., Feest T.G., Nassim M.A. Clonazepam: effective treatment for restless legs syndrome in uraemia. BMJ (Clin Res Ed) 1981, 283:885-886.
180. Ruottinen H.M., Partinen M., Hublin C., et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000, 54:502-504.
181. Rutkove S.B., Matheson J.K., Logigian E.L. Restless legs syndrome in patients with polyneuropathy. Muscle Nerve 1996, 19:670-672.
182. Sachdev P. Akathisia and Restless Legs 1995, Cambridge University Press, New York.
183. Saletu B., Gruber G., Saletu M., et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000, 41:181-189.
184. Saletu M., Anderer P., Saletu B., et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000, 41:190-199.
185. Saletu B., Anderer P., Saletu M., et al. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002, 3(Suppl):S35-S42.
186. Sanchez-Gonzalez M.A., Garcia-Cabezas M.A., Rico B., et al. The primate thalamus is a key target for brain dopamine. J Neurosci 2005, 25:6076-6083.
187. Schenck C.H., Mahowald M.W. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996, 100:333-337.
188. Schmidauer C., Sojer M., Seppi K., et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005, 58:630-634.
189. Schober T., Wenzel K., Feichtinger M., et al. Restless legs syndrome: changes of induced electroencephalographic beta oscillations-an ERD/ERS study. Sleep 2004, 27:147-150.
190. Schols L., Haan J., Riess O., et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?. Neurology 1998, 51:1603-1607.
191. Schormair B., Kemlink D., Roeske D., et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008, 40:946-948.
192. Sever Y., Ashkenazi A., Tyano S., et al. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology 1997, 35:178-180.
193. Sevim S., Dogu O., Camdeviren H., et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003, 61:1562-1569.
194. Siddiqui S., Kavanagh D., Traynor J., et al. Risk factors for restless legs syndrome in dialysis patients. Nephron Clin Pract 2005, 101:c155-c160.
195. Silber M.H., Shepard J.W., Wisbey J.A. Pergolide in the management of restless legs syndrome: an extended study. Sleep 1997, 20:878-882.
196. Silber M.H., Girish M., Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003, 26:819-821.
197. Silber M.H., Ehrenberg B.L., Allen R.P., et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004, 79:916-922.
198. Simakajornboon N., Gozal D., Vlasic V., et al. Periodic limb movements in sleep and iron status in children. Sleep 2003, 26:735-738.
199. Sloand J.A., Shelly M.A., Feigin A., et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
200. Smith M.J., Keel J.C., Greenberg B.D., et al. Menstrual cycle effects on cortical excitability. Neurology 1999, 53:2069-2072.
201. Spiegel K., Follenius M., Simon C., et al. Prolactin secretion and sleep. Sleep 1994, 17:20-27.
202. Staedt J., Wassmuth F., Ziemann U., et al. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus l-dopa. J Neural Transm 1997, 104:461-468.
203. Stefansson H., Rye D.B., Hicks A., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007, 357:639-647.
204. Stepanski E.J., Wyatt J.K. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003, 7:215-225.
205. Stiasny K., Robbecke J., Schuler P., et al. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline - an open clinical trial. Sleep 2000, 23:349-354.
206. Stiasny K., Wetter T.C., Winkelmann J., et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001, 56:1399-1402.
207. Stiasny-Kolster K., Oertel W.H. Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 2004, 50:65-70.
208. Stiasny-Kolster K., Haeske H., Tergau F., et al. Cortical silent period is shortened in restless legs syndrome independently from circadian rhythm. Suppl Clin Neurophysiol 2003, 56:381-389.
209. Stiasny-Kolster K., Benes H., Peglau I., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004, 63:2272-2279.
210. Stiasny-Kolster K., Kohnen R., Schollmayer E., et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004, 19:1432-1438.
211. Stiasny-Kolster K., Moller J.C., Zschocke J., et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord 2004, 19:192-196.
212. Sun E.R., Chen C.A., Ho G., et al. Iron and the restless legs syndrome. Sleep 1998, 21:371-377.
213. Suzuki K., Ohida T., Sone T., et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003, 26:673-677.
214. Tan E.K., Seah A., See S.J., et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001, 16:577-579.
215. Tan E.K., Lum S.Y., Wong M.C. Restless legs syndrome in Parkinson's disease. J Neurol Sci 2002, 196:33-36.
216. Telstad W., Sorensen O., Larsen S., et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. BMJ 1984, 288:444-446.
217. Tergau F., Wischer S., Paulus W. Motor system excitability in patients with restless legs syndrome. Neurology 1999, 52:1060-1063.
218. Tergau F., Wischer S., Wolf C., et al. Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov Disord 2001, 16:731-735.
219. Testa U. Proteins of Iron Metabolism 2002, CRC Press, New York.
220. Thorp M.L., Morris C.D., Bagby S.P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001, 38:104-108.
221. Tison F., Crochard A., Leger D., et al. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005, 65:239-246.
222. Trenkwalder C., Bucher S.F., Oertel W.H., et al. Bereitschaftspotential in idiopathic and symptomatic restless legs syndrome. Electroencephalogr Clin Neurophysiol 1993, 89:95-103.
223. Trenkwalder C., Stiasny K., Oertel W.H. [Therapy of idiopathic and uremic restless legs syndrome.]. Nervenarzt 1996, 67:265-276.
224. Trenkwalder C., Hening W.A., Walters A.S., et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord 1999, 14:102-110.
225. Trenkwalder C., Collado Seidel V., Kazenwadel J., et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?. Mov Disord 2003, 18:1184-1189.
226. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004, 75:92-97.
227. Trenkwalder C., Hundemer H.P., Lledo A., et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004, 62:1391-1397.
228. Tribl G.G., Asenbaum S., Happe S., et al. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun 2004, 25:55-60.
229. Tribl G.G., Sycha T., Kotzailias N., et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry 2005, 76:181-185.
230. 11C-raclopride PET studies. Neurology 1999, 52:932-937.
231. Ulfberg J., Nystrom B. Restless legs syndrome in blood donors. Sleep Med 2004, 5:115-118.
232. Ulfberg J., Nystrom B., Carter N., et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001, 16:1159-1163.
233. Ulfberg J., Nystrom B., Carter N., et al. Restless legs syndrome among working-aged women. Eur Neurol 2001, 46:17-19.
234. Unruh M.L., Levey A.S., D'Ambrosio C., et al. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004, 43:900-909.
235. Veldman R.G., Frolich M., Pincus S.M., et al. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. J Clin Endocrinol Metab 2001, 86:1562-1567.
236. Volavka J., Bauman J., Peunick J., et al. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 1980, 5:225-234.
237. Wagner M.L., Walters A.S., Coleman R.G., et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996, 19:52-58.
238. Waldstreicher J., Duffy J.F., Brown E.N., et al. Gender differences in the temporal organization of proclactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels - a clinical research center study. J Clin Endocrinol Metab 1996, 81:1483-1487.
239. Walters A.S. Restless legs syndrome and lumbosacral radiculopathy. Sleep Res 1996, 25:385.
240. Walters A.S., Hening W. Clinical presentation and neuropharmacology of restless legs syndrome. Clin Neuropharmacol 1987, 10:225-237. [published erratum appears in Clin Neuropharmacol 1987; 10: 482].
241. Walters A.S., Hening W.A., Kavey N., et al. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988, 24:455-458.
242. Walters A.S., Picchietti D., Hening W., et al. Variable expressivity in familial restless legs syndrome. Arch Neurol 1990, 47:1219-1220.
243. Walters A.S., Hening W., Rubinstein M., et al. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep 1991, 14:339-345.
244. Walters A.S., Wagner M.L., Hening W.A., et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993, 16:327-332.
245. Walters A.S., Aldrich M.A., Allen R.P., et al. Towards a better definition of the restless legs syndrome. Mov Disord 1995, 10:634-642.
246. Walters A.S., Hickey K., Maltzman J., et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996, 46:92-95.
247. Walters A.S., Mandelbaum D.E., Lewin D.S., et al. Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group. Pediatr Neurol 2000, 22:182-186.
248. Walters A.S., Winkelmann J., Trenkwalder C., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001, 16:1105-1109.
249. Walters A.S., Ondo W.G., Dreykluft T., et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004, 19:1414-1423.
250. Ware J.E., Snow K.K., Kosinski M., et al. SF-36 Health Survey - Manual and Interpretation Guide 1993, The Health Institute, New England Medical Center, Boston.
251. Wetter T.C., Kazenwadel J., Kohnen R., et al. A polysomnographic study of patients with uremic and idiopathic restless legs syndrome. Electroencephalogr Clin Neurophysiol 1996, 99:381.
252. Wetter T.C., Stiasny K., Winkelmann J., et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999, 52:944-950.
253. Wetter T.C., Collado-Seidel V., Oertel H., et al. Endocrine rhythms in patients with restless legs syndrome. J Neurol 2002, 249:146-151.
254. Willis T. De Animae Brutorum 1672, Wells and Scott, London.
255. Winkelman J.W., Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004, 5:9-14.
256. Winkelman J.W., Chertow G.M., Lazarus J.M. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996, 28:372-378.
257. Winkelmann J., Wetter T.C., Stiasny K., et al. Treatment of restless leg syndrome with pergolide - an open clinical trial. Mov Disord 1998, 13:566-569.
258. Winkelmann J., Wetter T.C., Collado-Seidel V., et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000, 23:597-602.
259. Winkelmann J., Schadrack J., Wetter T.C., et al. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med 2001, 2:57-61.
260. Winkelmann J., Muller-Myhsok B., Wittchen H.U., et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002, 52:297-302.
261. Winkelmann J., Stautner A., Samtleben W., et al. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002, 17:1072-1076.
262. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007, 39:1000-1006.
263. Wittchen H.U. Reliability and validity studies of the WHO - Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994, 28:57-84.
264. Young W.B., Piovesan E.J., Biglan K.M. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr 2003, 8:450-456.
265. Youssef E.A., Wagner M.L., Martinez J.O., et al. Pilot trial of lamotrigine in the restless legs syndrome. Sleep Med 2005, 6:89.
266. Zecca L., Berg D., Arzberger T., et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005, 20:1278-1285.
267. Ziemann U., Bruns D., Paulus W. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett 1996, 208:187-190.
268. Zucconi M., Oldani A., Castronovo C., et al. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep 2003, 26:815-818.